1-(3-C-ethynylribopentofuranosyl)uracil: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 176869 |
| SCHEMBL ID | 1650289 |
| MeSH ID | M0269626 |
| Synonym |
|---|
| 2,4(1h,3h)-pyrimidinedione, 1-(3-c-ethynyl-.beta.-d-ribofuranosyl)- |
| eurd |
| 1-[(2r,3r,4s,5r)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione |
| 3'-c-ethynyluridine |
| 1-(3'-c-ethynyl-beta-d-ribofuranosyl)uracil |
| 1-(3-c-ethynylribopentofuranosyl)uracil |
| uridine, 3'-c-ethynyl |
| 3-c-ethynyl-uridine |
| pj-272 |
| pj 272 |
| 180300-49-6 |
| SCHEMBL1650289 |
| DTXSID30170947 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||